Finally, we checked for the effect of TAK-981 on (i) TIGIT (inhibitory receptor) and DNAM1 (activating receptor), which compete for binding to PVR and Nectin-2 on cancer cells, and (i) LFA1, which binds to ICAM-1 and stabilizes NK interaction with their target cells (32). The gene discussed is CD226; the disease is cancer.